期刊
TOBACCO CONTROL
卷 19, 期 5, 页码 -出版社
BMJ PUBLISHING GROUP
DOI: 10.1136/tc.2009.035584
关键词
-
资金
- National Institute on Drug Abuse Rockville Maryland USA
- National Cancer Institute Rockville Maryland USA
- Nabi Biopharmaceuticals
Regulation of nicotine levels in cigarettes and other tobacco products is now possible with the passage of the Family Smoking Prevention and Tobacco Control Act (FSPTCA) in 2009 giving the US Food and Drug Administration (FDA) authority to regulate tobacco products and with Articles 911 of the WHO Framework Convention on Tobacco Control Both regulatory approaches allow establishing product standards for tobacco constituents including nicotine The FSPTCA does not allow nicotine levels to be decreased to rem although the FDA has the authority to reduce nicotine yields to very low presumably non addicting levels The proposal to reduce levels of nicotine to a level that is non addicting was originally suggested in 1994 Reduction of nicotine in tobacco products could potentially have a profound impact on reducing tobacco related morbidity and mortality To examine this issue two meetings were convened in the US with non tobacco industry scientists of varied disciplines tobacco control policymakers and representatives of government agencies This article provides an overview of the current science in the area of reduced nicotine content cigarettes and key conclusions and recommendations for research and policy that emerged from the deliberations of the meeting members
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据